J Exp Clin Cancer Res. 2024 Apr 23;43(1):123.doi: 10.1186/s13046-024-03048-1. (IF:12.658).

本文采用的英格恩产品: Entranster-H4000, Entranter-R4000

Tumor-suppressive miR-4732-3p is sorted into fucosylated exosome by hnRNPK to avoid the inhibition of lung cancer progression

Affiliations

Affiliations

  • 1 Shengli Clinical Medical College, Fujian Medical University, Fuzhou, 350001, China.
  • 2 Department of Clinical Laboratory, Fujian Provincial Hospital, Fuzhou, 350001, China.
  • 3 State Key Laboratory of Cellular Stress Biology, Innovation Center for Cell Signaling Network, School of Life Sciences, Xiamen University, Xiamen, 361102, China.
  • 4 Institute of Future Technology, Beijing Hotgen Biotech Co., Ltd, Beijing, 102600, China.
  • 5 Center for Experimental Research in Clinical Medicine, Fujian Provincial Hospital, Fuzhou, 350001, China.
  • 6 Department of Thoracic Surgery, Fujian Provincial Hospital, Fuzhou, 350001, China.
  • 7 Integrated Chinese and Western Medicine College, Fujian University of Traditional Chinese Medicine, Fuzhou, 350108, China.
  • 8 Department of Scientific Research, Fujian Provincial Hospital, Fuzhou, 350001, China.
  • 9 Department of Geriatric Medicine, Fujian Provincial Hospital, Fuzhou, 350001, China.
  • 10 Fujian Provincial Center for Geriatrics, Fujian Provincial Hospital, Fuzhou, 350001, China.
  • 11 Shengli Clinical Medical College, Fujian Medical University, Fuzhou, 350001, China. cdyu@xmu.edu.cn.
  • 12 State Key Laboratory of Cellular Stress Biology, Innovation Center for Cell Signaling Network, School of Life Sciences, Xiamen University, Xiamen, 361102, China. cdyu@xmu.edu.cn.
  • 13 Center for Experimental Research in Clinical Medicine, Fujian Provincial Hospital, Fuzhou, 350001, China. cdyu@xmu.edu.cn.
  • 14 Shengli Clinical Medical College, Fujian Medical University, Fuzhou, 350001, China. hyi8070@126.com.
  • 15 Department of Clinical Laboratory, Fujian Provincial Hospital, Fuzhou, 350001, China. hyi8070@126.com.
  • 16 Center for Experimental Research in Clinical Medicine, Fujian Provincial Hospital, Fuzhou, 350001, China. hyi8070@126.com.
  • 17 Fujian Provincial Center for Geriatrics, Fujian Provincial Hospital, Fuzhou, 350001, China. hyi8070@126.com.
  • 18 Central Laboratory, Fujian Provincial Hospital, Fuzhou, 350001, China. hyi8070@126.com.
  • 19 Fujian Provincial Key Laboratory of Critical Care Medicine, Fujian Provincial Key Laboratory of Cardiovascular Disease, Fuzhou, 350001, China. hyi8070@126.com.
# Contributed equally.

Abstract

Background: Aberrant fucosylation observed in cancer cells contributes to an augmented release of fucosylated exosomes into the bloodstream, where miRNAs including miR-4732-3p hold promise as potential tumor biomarkers in our pilot study. However, the mechanisms underlying the sorting of miR-4732-3p into fucosylated exosomes during lung cancer progression remain poorly understood.

Methods: A fucose-captured strategy based on lentil lectin-magnetic beads was utilized to isolate fucosylated exosomes and evaluate the efficiency for capturing tumor-derived exosomes using nanoparticle tracking analysis (NTA). Fluorescence in situ hybridization (FISH) and qRT-PCR were performed to determine the levels of miR-4732-3p in non-small cell lung cancer (NSCLC) tissue samples. A co-culture system was established to assess the release of miRNA via exosomes from NSCLC cells. RNA immunoprecipitation (RIP) and miRNA pull-down were applied to validate the interaction between miR-4732-3p and heterogeneous nuclear ribonucleoprotein K (hnRNPK) protein. Cell functional assays, cell derived xenograft, dual-luciferase reporter experiments, and western blot were applied to examine the effects of miR-4732-3p on MFSD12 and its downstream signaling pathways, and the impact of hnRNPK in NSCLC.

Results: We enriched exosomes derived from NSCLC cells using the fucose-captured strategy and detected a significant upregulation of miR-4732-3p in fucosylated exosomes present in the serum, while its expression declined in NSCLC tissues. miR-4732-3p functioned as a tumor suppressor in NSCLC by targeting 3’UTR of MFSD12, thereby inhibiting AKT/p21 signaling pathway to induce cell cycle arrest in G2/M phase. NSCLC cells preferentially released miR-4732-3p via exosomes instead of retaining them intracellularly, which was facilitated by the interaction of miR-4732-3p with hnRNPK protein for selective sorting into fucosylated exosomes. Moreover, knockdown of hnRNPK suppressed NSCLC cell proliferation, with the elevated levels of miR-4732-3p in NSCLC tissues but the decreased expression in serum fucosylated exosomes.

Conclusions: NSCLC cells escape suppressive effects of miR-4732-3p through hnRNPK-mediated sorting of them into fucosylated exosomes, thus supporting cell malignant properties and promoting NSCLC progression. Our study provides a promising biomarker for NSCLC and opens a novel avenue for NSCLC therapy by targeting hnRNPK to prevent the “exosome escape” of tumor-suppressive miR-4732-3p from NSCLC cells.

Keywords: Exosome escape; Fucosylated exosome; MFSD12; hnRNPK; miR-4732-3p.

在线客服
在线客服
热线电话
 
0
    0
    我的购物车
    购物车是空的去下单